Detroit-based Barbara Ann Karmanos Cancer Institute has become the first independent cancer center in the U.S. to provide a one-time gene therapy for the treatment of hemophilia B in adults.
The first patient received the therapy — called Hemgenix — Oct. 28, according to a March 23 news release from the cancer institute.
The standard treatment for hemophilia B requires routine infusions of factor IX replacement therapy to help reduce bleeding risk. After gene therapy, patients need infusions only when undergoing a medical procedure or experiencing physical trauma.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.